Skip to main content
SpringerLink
Log in

Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors

  • Chapter
  • First Online:
Neuroendocrine Tumors

  • 505 Accesses

Abstract

The incidence of neuroendocrine tumors (NETs), particularly of locoregional NETs, is increasing. Given this trend in presentation, more patients are being considered for surgical resection. Perioperative therapy in other solid tumors has become standard of care as metastatic spread or recurrence lead to reduced overall survival for patients. Currently, it is unclear whether such an approach is relevant for well-differentiated NET patients where disease recurrence may occur much later and even then, with typically an indolent disease course. Though some small retrospective studies in gastroenteropancreatic (GEP) NET patients have suggested improved outcomes in patients who receive perioperative therapy, others have not. Further, no prospective studies have been completed to validate this approach. Several prospective perioperative therapy studies for GEP NET patients are ongoing but others have been terminated due to slow accrual.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dasari A, Shen C, Halperin D, Zhao B, Zhou Z, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chauhan A, Kohn E, Del Rivero J. Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence. JAMA Oncol. 2020;6(1):21–2.

    Article  PubMed  Google Scholar 

  3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares J, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

    Article  PubMed  Google Scholar 

  4. Hallet J, Law C, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–97.

    Article  PubMed  Google Scholar 

  5. Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, et al. Lancet. 2019;393(10184):1948–57.

    Article  PubMed  Google Scholar 

  6. Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul J, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.

    Article  CAS  PubMed  Google Scholar 

  7. van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, Henegouwen v WB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.

    Article  PubMed  Google Scholar 

  8. Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Paul J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Singh S, Chan D, Moody L, Liu N, Fischer H, Austin P, et al. Recurrence in resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol. 2018;4(4):583–5.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Cives M, Anaya D, Soares H, Coppola D, Strosberg J. Analysis of postoperative recurrence in stage I–III midgut neuroendocrine tumors. J Natl Cancer Inst. 2018;110(3):282–9.

    Article  PubMed  Google Scholar 

  11. Lou F, Sarkaria I, Pietanza C, Healy D, Rusch V, Huang J, et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg. 2013;96(4):1156–62.

    Article  PubMed  Google Scholar 

  12. Lee P, Osakwe N, Narula N, Port J, Paul S, Stiles B, et al. Predictors of disease-free survival and recurrence in patients with resected bronchial carcinoid tumors. Thorac Cardiovasc Surg. 2016;64(2):159–65.

    PubMed  Google Scholar 

  13. Singh S, Moody L, Chan D, Metz D, Strosberg J, Amis T, et al. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol. 2018;4(11):1597–604.

    Article  PubMed  Google Scholar 

  14. Zaidi M, Lopez-Aguilar A, Switchenko J, Lipscomb J, Andreasi V, Partelli S, et al. A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors. Ann Surg. 2019;270(3):422–33.

    Article  PubMed  Google Scholar 

  15. Tsutumi K, Ohtsuka T, Fujino M, Nakshima H, Aishima S, Ueda J, et al. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepatobiliary Pancreatic Sci. 2014;21(6):418–25.

    Article  Google Scholar 

  16. Genc CG, Falconi M, Partelli S, Muffatti F, van Eeden S, Doglioni C, et al. Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol. 2018;25(8):2467–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lopez-Aguilar A, Ethun C, Zaidi M, Rocha F, Poultsides G, Dillhoff M, et al. The conundrum of < 2-cm pancreatic neuroendocrine tumors: a preoperative risk score to predict lymph node metastases and guide surgical management. Surgery. 2019;166(1):15–21.

    Article  Google Scholar 

  18. Sallinen V, Le Large T, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik S, et al. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors – a multi-institutional study. HPB (Oxford). 2017;20(3):251–9.

    Article  Google Scholar 

  19. Mansour J, Chavin K, Morris-Stiff G, Warner S, Cardona K, et al. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB (Oxford). 2019;21(5):515–23.

    Article  Google Scholar 

  20. Kim J, Brosnan-Cashman J, An S, Kim S, Song K, Kim M, et al. Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res. 2017;23(6):1598–606.

    Article  CAS  PubMed  Google Scholar 

  21. Singhi A, Liu T, Roncaioli J, et al. Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res. 2017;23(2):600–9.

    Article  CAS  PubMed  Google Scholar 

  22. Cejas P, Drier Y, Dreijerink K, Lodewijk DV, Epstein C, et al. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019;25(8):1260–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Karpathakis A, Dibra H, Pipinkas C, Feber A, Morris T, Francis J, et al. Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res. 2016;22(1):250–8.

    Article  CAS  PubMed  Google Scholar 

  24. Stalberg P, Westin G, Thirlwell C. Genetics and epigenetics in small intestinal neuroendocrine tumours. J Intern Med. 2016;280(6):584–94.

    Article  CAS  PubMed  Google Scholar 

  25. Shi X, Xu X, Zhang Y, Gao S, Li B, Ma H, et al. Using long-acting somatostatin analogue as adjuvant therapy for post resection grade 2 pancreatic neuroendocrine tumor: interim results from an ongoing multicenter real-world study in China. ENETS. 2019; Abstract #2899

    Google Scholar 

  26. Squires M, Worth P, Konda B, Shah M, Dillhoff M, Abdel-Misih S, et al. Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors. Pancreas. 2020;49(3):355–60.

    Article  CAS  PubMed  Google Scholar 

  27. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, et al. Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors. J Gastrointest Surg. 2017;21(1):155–63.

    Article  PubMed  Google Scholar 

  28. Kouvaraki M, Ajani J, Hoff P, Wolff R, Evans D, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762–71.

    Article  CAS  PubMed  Google Scholar 

  29. Lam M, Rogers J, Halperin D, Dagohoy C, Yao J, Dasari A. Outcomes with 5-Fluorouracil, Doxorubicin, and Streptozocin (FAS) and subsequent therapies in patients with well differentiated Pancreatic Neuroendocrine Tumors (PanNETs). Pancreas. 2019;48(3):427–57.

    Google Scholar 

  30. Perysinakis I, Aggeli C, Kaltsas G, Zografos G. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality? Hormones (Athens). 2016;15(1):15–22.

    Article  Google Scholar 

  31. Sabet A, Biersack H-J, Ezziddin S, et al. Advances in peptide receptor radionuclide therapy. Semin Nucl Med. 2016;46(1):40–6.

    Article  PubMed  Google Scholar 

  32. Sowa-Staszczak A, Hubalewska-Dydejczyk A, Tomaszuk M. PRRT as neoadjuvant treatment in NET. Recent Results Cancer Res. 2013;194:479–85.

    Article  CAS  PubMed  Google Scholar 

  33. van Vliet E, van Eijick C, de Krijger R, Nieveen van Dijkum E, Teunissen J, Kam B, et al. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]Octreotate. J Nucl Med. 2015;56(11):1647–53.

    Article  PubMed  CAS  Google Scholar 

  34. Partelli S, Bertani E, Bartolomei M, Perali C, Muffati F, Maria Grana C, et al. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2018;163(4):761–7.

    Article  PubMed  Google Scholar 

  35. Xie H, Liu J, Yadav S, Keutgen X, Hobday T, Strosberg J, et al. The role of perioperative systemic therapy in localized pancreatic neuroendocrine neoplasms. Neuroendocrinology. 2020;110(3–4):234–45.

    Google Scholar 

  36. Wang Y, Chauhan A, Ramirez R, Beyer D, Stevens M, Woltering E, et al. Does the addition of adjuvant intraoperative tumor bed chemotherapy during midgut neuroendocrine tumor debulking procedures benefit patients? J Gastrointest Oncol. 2019;10(5):928–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Barrett J, Rendell V, Pokrzywa C, Lopez-Aguilar A, Cannon J, Poultsides G, et al. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol. 2020;121(7):1067–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lamberti G, Manuzzi L, Maggio I, Campana D. Should we lose hope in adjuvant therapy for neuroendocrine tumors?-in response to: adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol. 2020;122(3):570–1.

    Article  PubMed  Google Scholar 

  39. Nussbaum D, Speicher P, Gulack B, Hartwig M, Onaitis M, D’Amico T, et al. Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Ann Thorac Surg. 2015;99:428–34.

    Article  PubMed  Google Scholar 

  40. Anderson K, Mulvihill M, Speicher P, D’Amico T, Berry M, Hartwig M, et al. Adjuvant chemotherapy does not confer superior survival in patients with atypical carcinoid tumors. Ann Thorac Surg. 2017;104(4):1221–30.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Howe J, Merchant N, Conrad C, Keutgen X, Hallet J, Drebin J, et al. The north American neuroendocrine tumor society consensus paper on the surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:1–33.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.

    Article  CAS  PubMed  Google Scholar 

  43. NCCN Guidelines Panel. Neuroendocrine and adrenal tumors. Available from: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

  44. Strosberg J, Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kunz P, Catalano P, Nimeiri H, Fisher G, Longacre T, Suarez C, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOGACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15_suppl):4004.

    Article  Google Scholar 

  46. Jones G, Manchanda P, Pringle D, Zhang M, Kirschner L. Mouse models of endocrine tumors. Best Pract Res Clin Endocrinol Metab. 2011;24(3):451–60.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vanderbilt University Medical Center, Department of Medicine, Division of Hematology and Oncology, Nashville, TN, USA

    Satya Das

  2. Huntsman Cancer Institute at University of Utah, Division of Oncology, Salt Lake City, UT, USA

    Heloisa Soares

  3. The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, TX, USA

    Arvind Dasari

Authors
  1. Satya Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heloisa Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arvind Dasari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arvind Dasari .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Jordan M. Cloyd

  2. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Timothy M. Pawlik

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Das, S., Soares, H., Dasari, A. (2021). Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors. In: Cloyd, J.M., Pawlik, T.M. (eds) Neuroendocrine Tumors. Springer, Cham. https://doi.org/10.1007/978-3-030-62241-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62241-1_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62240-4

  • Online ISBN: 978-3-030-62241-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation